On Wednesday, ARK Invest sold about 3,578 shares of Meta Platforms across three of its funds. These shares were worth roughly $2.1 million at the closing price. At the same time, ARK invested in healthcare technology company Tempus AI. This move shows how one of the market’s most closely watched managers is adjusting its approach to AI investments.
The timing of ARK’s Meta sale stood out. Meta shares rose 0.3% Wednesday, despite negative news: a major trial verdict finding the company negligent for harm to minors, layoffs in several divisions, and investor concerns about an ambitious executive compensation plan aiming for a 500% stock price increase and a $9 trillion valuation by 2031. This early strength faded quickly, with Meta shares dropping 4.6% early Thursday, supporting ARK’s decision to sell.
Most of the Meta shares sold came from the ARK Innovation ETF. This ETF now holds about 105,000 Meta shares, worth around $63 million. This accounts for roughly 1% of the fund and ranks as its 32nd-largest position among 44 holdings. The smaller stake shows that ARK is intentionally giving Meta less importance in its main investment strategy.
ARK used the proceeds to buy Tempus AI shares. The ARK Innovation ETF bought 72,290 shares worth about $3.3 million. The ARK Genomic Revolution fund added another 12,649 shares. This looks like a careful dip-buying move. Tempus AI dropped 4.2% on Wednesday and is down about 20% year to date. This gave ARK a chance to buy at a lower price. Tempus AI then rose 1.3% in early Thursday trading, while Meta’s stock is now among ARK’s top positions as its third-largest holding in the ARK Innovation ETF, with 6.3 million shares valued at over $294 million, about 5% of the fund. For traders tracking ARK’s daily moves as signals for AI and healthcare tech trends, this shift marks a real change in ARK’s focus. The firm is moving from major social media companies to AI-powered healthcare analytics, which could drive the next phase of artificial intelligence investing.
